Cargando…

Lymphangioleiomyomatosis: Searching for potential biomarkers

BACKGROUND: Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM is crucial. The aim of this study was to describe the diagnostic ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Revilla-López, Eva, Ruiz de Miguel, Victoria, López-Meseguer, Manuel, Berastegui, Cristina, Boada-Pérez, Meritxell, Mendoza-Valderrey, Alberto, Arjona-Peris, Marta, Zapata-Ortega, Marta, Monforte, Victor, Bravo, Carlos, Roman, Antonio, Gómez-Ollés, Susana, Sáez-Giménez, Berta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931739/
https://www.ncbi.nlm.nih.gov/pubmed/36817769
http://dx.doi.org/10.3389/fmed.2023.1079317
_version_ 1784889298753945600
author Revilla-López, Eva
Ruiz de Miguel, Victoria
López-Meseguer, Manuel
Berastegui, Cristina
Boada-Pérez, Meritxell
Mendoza-Valderrey, Alberto
Arjona-Peris, Marta
Zapata-Ortega, Marta
Monforte, Victor
Bravo, Carlos
Roman, Antonio
Gómez-Ollés, Susana
Sáez-Giménez, Berta
author_facet Revilla-López, Eva
Ruiz de Miguel, Victoria
López-Meseguer, Manuel
Berastegui, Cristina
Boada-Pérez, Meritxell
Mendoza-Valderrey, Alberto
Arjona-Peris, Marta
Zapata-Ortega, Marta
Monforte, Victor
Bravo, Carlos
Roman, Antonio
Gómez-Ollés, Susana
Sáez-Giménez, Berta
author_sort Revilla-López, Eva
collection PubMed
description BACKGROUND: Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM is crucial. The aim of this study was to describe the diagnostic accuracy of a variety of biomarkers. METHODS: We assessed 13 analytes in serum related to extracellular matrix remodeling, lymphatic involvement and angiogenesis in a cohort of patients with LAM, comparing them with patients with other cystic lung diseases (OCLD) and healthy women. A scoring method based on the cut-point of each VEGF-D and metalloproteinase-2 (MMP-2) was used to evaluate the diagnostic performance of the marker combination. RESULTS: A total of 97 subjects were recruited: 59 (61%) LAM patients, 18 (19%) OCLD patients, and 20 (20%) healthy female controls. MMP-2 was the only extracellular matrix remodeling biomarker able to differentiate LAM patients from OCLD and healthy patients. Serum MMP-2 was higher in LAM patients [median 578 (465–832) ng/ml] than in patients with OCLD and healthy controls [medians 360 (314–546) and 427 (365–513) ng/ml, respectively (p < 0.0001)]. The area under ROC curve (AUC) of MMP-2 was 0.785 and that of VEGF-D 0.815 (p = 0.6214). The sensitivity/specificity profiles of each biomarker (54/92% for MMP-2, 59/95% for VEGF-D) yielded a composite score (−6.36 + 0.0059 × VEGF-D + 0.0069 × MMP-2) with higher accuracy than each component alone (AUC 0.88 and sensitivity/specificity 79/87%). CONCLUSION: Combining MMP-2 and VEGF-D may increase diagnostic accuracy for LAM.
format Online
Article
Text
id pubmed-9931739
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99317392023-02-17 Lymphangioleiomyomatosis: Searching for potential biomarkers Revilla-López, Eva Ruiz de Miguel, Victoria López-Meseguer, Manuel Berastegui, Cristina Boada-Pérez, Meritxell Mendoza-Valderrey, Alberto Arjona-Peris, Marta Zapata-Ortega, Marta Monforte, Victor Bravo, Carlos Roman, Antonio Gómez-Ollés, Susana Sáez-Giménez, Berta Front Med (Lausanne) Medicine BACKGROUND: Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM is crucial. The aim of this study was to describe the diagnostic accuracy of a variety of biomarkers. METHODS: We assessed 13 analytes in serum related to extracellular matrix remodeling, lymphatic involvement and angiogenesis in a cohort of patients with LAM, comparing them with patients with other cystic lung diseases (OCLD) and healthy women. A scoring method based on the cut-point of each VEGF-D and metalloproteinase-2 (MMP-2) was used to evaluate the diagnostic performance of the marker combination. RESULTS: A total of 97 subjects were recruited: 59 (61%) LAM patients, 18 (19%) OCLD patients, and 20 (20%) healthy female controls. MMP-2 was the only extracellular matrix remodeling biomarker able to differentiate LAM patients from OCLD and healthy patients. Serum MMP-2 was higher in LAM patients [median 578 (465–832) ng/ml] than in patients with OCLD and healthy controls [medians 360 (314–546) and 427 (365–513) ng/ml, respectively (p < 0.0001)]. The area under ROC curve (AUC) of MMP-2 was 0.785 and that of VEGF-D 0.815 (p = 0.6214). The sensitivity/specificity profiles of each biomarker (54/92% for MMP-2, 59/95% for VEGF-D) yielded a composite score (−6.36 + 0.0059 × VEGF-D + 0.0069 × MMP-2) with higher accuracy than each component alone (AUC 0.88 and sensitivity/specificity 79/87%). CONCLUSION: Combining MMP-2 and VEGF-D may increase diagnostic accuracy for LAM. Frontiers Media S.A. 2023-02-02 /pmc/articles/PMC9931739/ /pubmed/36817769 http://dx.doi.org/10.3389/fmed.2023.1079317 Text en Copyright © 2023 Revilla-López, Ruiz de Miguel, López-Meseguer, Berastegui, Boada-Pérez, Mendoza-Valderrey, Arjona-Peris, Zapata-Ortega, Monforte, Bravo, Roman, Gómez-Ollés and Sáez-Giménez. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Revilla-López, Eva
Ruiz de Miguel, Victoria
López-Meseguer, Manuel
Berastegui, Cristina
Boada-Pérez, Meritxell
Mendoza-Valderrey, Alberto
Arjona-Peris, Marta
Zapata-Ortega, Marta
Monforte, Victor
Bravo, Carlos
Roman, Antonio
Gómez-Ollés, Susana
Sáez-Giménez, Berta
Lymphangioleiomyomatosis: Searching for potential biomarkers
title Lymphangioleiomyomatosis: Searching for potential biomarkers
title_full Lymphangioleiomyomatosis: Searching for potential biomarkers
title_fullStr Lymphangioleiomyomatosis: Searching for potential biomarkers
title_full_unstemmed Lymphangioleiomyomatosis: Searching for potential biomarkers
title_short Lymphangioleiomyomatosis: Searching for potential biomarkers
title_sort lymphangioleiomyomatosis: searching for potential biomarkers
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931739/
https://www.ncbi.nlm.nih.gov/pubmed/36817769
http://dx.doi.org/10.3389/fmed.2023.1079317
work_keys_str_mv AT revillalopezeva lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT ruizdemiguelvictoria lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT lopezmeseguermanuel lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT berasteguicristina lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT boadaperezmeritxell lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT mendozavalderreyalberto lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT arjonaperismarta lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT zapataortegamarta lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT monfortevictor lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT bravocarlos lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT romanantonio lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT gomezollessusana lymphangioleiomyomatosissearchingforpotentialbiomarkers
AT saezgimenezberta lymphangioleiomyomatosissearchingforpotentialbiomarkers